Quick links
Home 
Commercialization First Commercial Product
Commercialization First Commercial Product
| First Commercial Product |
 |
 |
|
Topical Ointment for Skin Cancer (BSCT)
Biosceptre has developed a polyclonal antibody which is formulated into an ointment for topical use in treating non-melanoma skin cancers.
The first patient successfully treated with the Biosceptre antibody ointment was a female with a papulonodular basal cell carcinoma (BCC) on her ear - a very serious condition. The pinna of her ear was due to be surgically removed, but after twice daily treatment with the Biosceptre antibody ointment, the lesion disappeared after 10 days. 5 years later, the BCC has not returned (see below):
 Subsequent to this experience a leading Sydney dermatologist used the Biosceptre antibody ointment to treat a number of patients suffering from a range of different skin cancers. No side-effects were reported. While this work was originally designed to be only a proof of concept test for systemic cancer treatment applications, the results were so encouraging that the Company decided to develop a topical product for non-melanoma skin cancers.
Biosceptre expects to commence Phase I and Phase IIa clinical trials of this product in the US later in 2011, and it is estimated that this will be completed in approximately two years.
|